M. Żelezik, A. Michalska, K. Kapturska, A. Michalska, A. Niewiadomska, Jarosław Miszczuk, M. Sadowski
Introduction: The prevalence of abdominal aorta aneurysms (AAA) is estimated to be between 1.3–12.5% in men and 5.2% in women, which poses a serious public health issue. Ruptured aorta aneurysm most often causes internal bleeding and ultimately leads to death. The cause of high mortality is the asymptomatic occurrence of AAA. Usually, the first symptom is its rupture The aim of our paper is to provide a relationship between the percentage of the population reporting to the vascular surgeon and the type of residence based on the analysis of data from screening studies carried out in one of the regions of Poland. Material and methods: Patients previously informed about the free diagnostics in the Provincial Hospital in Kielce were examined by qualified physicians with ESAOTE MyLab Seven ultrasound device. Prior to that, patients were asked to fill a questionnaire to acquire data about their risk factors, demography, and medical history. Results: A total of 22 (7.3%) aneurysms were found in a group of 301 patients, of which 20 (6.6%) were found in men and 2 (0.66%) in women. Conclusions: Screening tests are an effective method to significantly improve early detection of AAAs. However, it is necessary to provide easier access to health professionals qualified to perform ultrasound examinations. It is especially important for the population of men with a family history of AAA, because they are at a higher risk of developing this pathology. The incidence rate of AAA observed in our study is consistent with the data published in worldwide literature.
{"title":"Abdominal aorta aneurysm screening program in Swietokrzyskie Voivodeship: early results","authors":"M. Żelezik, A. Michalska, K. Kapturska, A. Michalska, A. Niewiadomska, Jarosław Miszczuk, M. Sadowski","doi":"10.5603/aa.2019.0012","DOIUrl":"https://doi.org/10.5603/aa.2019.0012","url":null,"abstract":"Introduction: The prevalence of abdominal aorta aneurysms (AAA) is estimated to be between 1.3–12.5% in men and 5.2% in women, which poses a serious public health issue. Ruptured aorta aneurysm most often causes internal bleeding and ultimately leads to death. The cause of high mortality is the asymptomatic occurrence of AAA. Usually, the first symptom is its rupture The aim of our paper is to provide a relationship between the percentage of the population reporting to the vascular surgeon and the type of residence based on the analysis of data from screening studies carried out in one of the regions of Poland. Material and methods: Patients previously informed about the free diagnostics in the Provincial Hospital in Kielce were examined by qualified physicians with ESAOTE MyLab Seven ultrasound device. Prior to that, patients were asked to fill a questionnaire to acquire data about their risk factors, demography, and medical history. Results: A total of 22 (7.3%) aneurysms were found in a group of 301 patients, of which 20 (6.6%) were found in men and 2 (0.66%) in women. Conclusions: Screening tests are an effective method to significantly improve early detection of AAAs. However, it is necessary to provide easier access to health professionals qualified to perform ultrasound examinations. It is especially important for the population of men with a family history of AAA, because they are at a higher risk of developing this pathology. The incidence rate of AAA observed in our study is consistent with the data published in worldwide literature.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49600102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Iłżecki, P. Terlecki, S. Przywara, J. Iłżecka, T. Zubilewicz
Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/ /SSV superficial venous insufficiency using Flebogrif® catheter, the safety of the method, expressed in number and quality of observed complications in 24-month observation. Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process. All patients signed the informed consent form approved by the Bioethics Committee of the Medical University of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV. Each patient was treated with a compression agent in the form of a second compression class elastic stockings (20–30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36 months after the procedure. Results: During 24 months of observation, the evaluation of the Flebogrif® catheter method was based on the analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number of successfully closed veins ablated with the Flebogrif® catheter to the number of observed cases of recanalization; clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of the method, expressed in terms of quantity and quality of observed complications; technical characteristics of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of the observed complications allow considering the procedure of vein ablation with the use of Flebogrif® catheter as safe, possible to perform in ambulatory conditions. Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statistically significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of complications allows to consider the method safe; the method of surgery allows to perform the procedure in ambulatory conditions.
{"title":"The novel minimally invasive mechano-chemical technique of the saphenous vein ablation. Our center experience: results of 24 months follow-up","authors":"M. Iłżecki, P. Terlecki, S. Przywara, J. Iłżecka, T. Zubilewicz","doi":"10.5603/aa.2019.0008","DOIUrl":"https://doi.org/10.5603/aa.2019.0008","url":null,"abstract":"Introduction: The aim of the study was to evaluate the efficacy of the endovascular ablation method of GSV/ /SSV superficial venous insufficiency using Flebogrif® catheter, the safety of the method, expressed in number and quality of observed complications in 24-month observation. Material and methods: Initially, the observed group included 200 patients undergoing ablation of insufficient GSV/SSV. During 24 months of observation, this number decreased to 158, which seems to be a natural process. All patients signed the informed consent form approved by the Bioethics Committee of the Medical University of Lublin. Based on clinical evaluation, including ultrasound assessment, 200 patients, including 170 women and 30 men, were admitted to the study using the adopted criteria of inclusion/exclusion. In the studied group of patients, 172 great saphenous veins (GSV) and 28 short saphenous veins (SSV) were ablated. The treated inefficient veins were punctured at three levels depending on the length of the segment of insufficient GSV/SSV. Each patient was treated with a compression agent in the form of a second compression class elastic stockings (20–30 mm Hg). Control visits on the basis of the accepted protocol were established in 1, 3, 6, 12, 24, 36 months after the procedure. Results: During 24 months of observation, the evaluation of the Flebogrif® catheter method was based on the analysis of results obtained in four categories: effectiveness of the method, expressed as the ratio of the number of successfully closed veins ablated with the Flebogrif® catheter to the number of observed cases of recanalization; clinical improvement of venous insufficiency symptoms, based on the VCSS, CEAP, VAPS scale; safety of the method, expressed in terms of quantity and quality of observed complications; technical characteristics of the method. The obtained results were analyzed statistically using tests for non-parametric variables. The effectiveness of the method based on the obtained results was 92%. A statistically significant decrease in the intensity of clinical symptoms in relation to the preoperative condition was observed. The number and quality of the observed complications allow considering the procedure of vein ablation with the use of Flebogrif® catheter as safe, possible to perform in ambulatory conditions. Conclusions: Effectiveness of the method of 92% in 24-month observation; good cosmetic effect; a statistically significant decrease in the intensity of clinical symptoms in 24-month observation; the low incidence of complications allows to consider the method safe; the method of surgery allows to perform the procedure in ambulatory conditions.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46577497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Shaker, H. Khairy, K. Elkaffas, Ahmed Abdelhafez Ghanem
Introduction: To know frequency of abdominal aortic aneurysm (AAA) using ultrasound and clarify associated risk factors in 1000 Egyptians. Material and methods: Prospective study. 1000 patients aged 50 years or more (mean: 57.97 ± [7.68]) were examined by B-mode ultrasound at our radiology department to measure suprarenal maximum diameter of the abdominal aorta (wall to wall measurement) and to identify the occurrence of AAA (aneurysms were defined as 1.5 times the mean diameter). Demographic data and risk factors were also noted. Results: Mean aortic diameter in study population was 18.9 ± (3.2) mm. AAA diameter was 28.3 mm. Frequency of AAA was 1.5%. AAA prevalence: 2.35% in males versus 0.75% in females. Prevalence of AAA in different age groups: 70 years (n = 65) was 6 (0.9%), 6 (2.1%), 3 (4.6%) respectively. Patients with AAA were older (P < 0.001), more often male (P < 0.001), smokers (P < 0.001). Conclusion: Study showed that mean aortic diameter was 18.9 mm and AAA is present in 1.5% of the study population which was less than that seen in previously conducted studies in other countries.
{"title":"Frequency of abdominal aortic aneurysm in persons who have been examined with ultrasound at Kasr Al-Ainy Hospitals: a single center pilot study","authors":"A. Shaker, H. Khairy, K. Elkaffas, Ahmed Abdelhafez Ghanem","doi":"10.5603/aa.2019.0011","DOIUrl":"https://doi.org/10.5603/aa.2019.0011","url":null,"abstract":"Introduction: To know frequency of abdominal aortic aneurysm (AAA) using ultrasound and clarify associated risk factors in 1000 Egyptians. Material and methods: Prospective study. 1000 patients aged 50 years or more (mean: 57.97 ± [7.68]) were examined by B-mode ultrasound at our radiology department to measure suprarenal maximum diameter of the abdominal aorta (wall to wall measurement) and to identify the occurrence of AAA (aneurysms were defined as 1.5 times the mean diameter). Demographic data and risk factors were also noted. Results: Mean aortic diameter in study population was 18.9 ± (3.2) mm. AAA diameter was 28.3 mm. Frequency of AAA was 1.5%. AAA prevalence: 2.35% in males versus 0.75% in females. Prevalence of AAA in different age groups: 70 years (n = 65) was 6 (0.9%), 6 (2.1%), 3 (4.6%) respectively. Patients with AAA were older (P < 0.001), more often male (P < 0.001), smokers (P < 0.001). Conclusion: Study showed that mean aortic diameter was 18.9 mm and AAA is present in 1.5% of the study population which was less than that seen in previously conducted studies in other countries.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46309466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article presents a review of the literature assessing the effectiveness and safety of sulodexide in the prophylaxis of deep vein thrombosis and treatment of chronic venous disease. It was demonstrated that sulodexide is effective and safe in the prophylaxis of deep vein thrombosis and treatment of chronic venous insufficiency with ulcers. Sulodexide is characterized by low frequency of bleeding complications.
{"title":"Effectiveness and safety of sulodexide in the treatment of venous diseases","authors":"W. Tomkowski, M. Dybowska","doi":"10.5603/aa.2019.0014","DOIUrl":"https://doi.org/10.5603/aa.2019.0014","url":null,"abstract":"This article presents a review of the literature assessing the effectiveness and safety of sulodexide in the prophylaxis of deep vein thrombosis and treatment of chronic venous disease. It was demonstrated that sulodexide is effective and safe in the prophylaxis of deep vein thrombosis and treatment of chronic venous insufficiency with ulcers. Sulodexide is characterized by low frequency of bleeding complications.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48591800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Piotr Pukacki, R. Juszkat, M. Błaszyk, Ł. Dzieciuchowicz, Z. Krasiński
Upper extremity deep vein thrombosis (UEDVT) may be the first manifestation of venous thoracic outlet syndrome (VTOS). It primarily affects young, physically active people. The clinical findings depend on the degree of obstruction of the subclavian vein. Correct diagnosis — aided by various imaging modalities — as well as rapid initiation of local thrombolytic therapy, surgical decompression of the thoracic outlet (when indications are present), and the immediate initiation of anticoagulation therapy aim at successfully restoring the patient’s quality of life.
{"title":"Upper extremity deep vein thrombosis: pathogenesis and treatment","authors":"Piotr Pukacki, R. Juszkat, M. Błaszyk, Ł. Dzieciuchowicz, Z. Krasiński","doi":"10.5603/AA.2019.0010","DOIUrl":"https://doi.org/10.5603/AA.2019.0010","url":null,"abstract":"Upper extremity deep vein thrombosis (UEDVT) may be the first manifestation of venous thoracic outlet syndrome (VTOS). It primarily affects young, physically active people. The clinical findings depend on the degree of obstruction of the subclavian vein. Correct diagnosis — aided by various imaging modalities — as well as rapid initiation of local thrombolytic therapy, surgical decompression of the thoracic outlet (when indications are present), and the immediate initiation of anticoagulation therapy aim at successfully restoring the patient’s quality of life.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45597897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Krasiński, Z. Gaciong, F. Szymanski, R. Kowalewski, T. Urbanek
Peripheral artery disease (PAD) is a common disease, though not very well known and often diagnosed on a very late stage, causing not only typical complications such as intermittent claudication, critical limb ischemia or amputations, but also to cardiovascular mortality. The risk of cardiovascular death can be even 11 times higher in patients with symptomatic PAD than in healthy patients. The risk of heart attack, stroke or cardiovascular death is even higher, reaching almost 4% within one year, nearly equal to the risk for patients with coronary artery disease (CAD). In those patients, the 5-year mortality risk is estimated at 10–15%, with cardiovascular disorders being the most likely cause of death. In patients with critical limb ischemia, the risk of cardiovascular death within one year can be as high as 25% and the risk of amputation — 30%. It is estimated that the global population of patients with PAD is over 120 million. The incidence of the diseases is 3–10%, but in patients aged 70 and more, the incidence increases to 14–29%. In Poland, around 4,000 people are hospitalized every year for PAD of lower limbs. The number of PAD-related amputations is over 9,000 per year. Although the methods of PAD diagnosis (e.g. ABI) are often easy and non-invasive, they are scarcely used in clinical practice. Also, optimal conservative management in the form of quitting smoking, modifying the cardiovascular risk factors and supervised exercise is often overlooked. PAD is a major issue not only for vascular surgery, but also for many other medical specializations, including angiology, general medicine, cardiology, or diabetology. As a result of long waiting times for the next visit and lack of access to patient programmes and reimbursed drugs, patients with PAD often report to the doctor when their condition is very serious. Despite the 2017 ESC guidelines on the diagnosis and treatment of peripheral artery disease, prepared together with ESVS, not all healthcare professionals have access to the latest knowledge on PAD diagnosis and treatment. Unfortunately, though published recently, the ESC’s guidelines do not include some of the recent studies, among them the possibly breakthrough COMPASS trial which has the potential to change the paradigm of management of patients with PAD. We must bear in mind that the population with PAD is a difficult patient group who need new treatment methods and optimization of the existing ones in order to visibly improve diagnosis, treatment and prognosis.
{"title":"The position of Polish experts on conservative management in patients with artery diseases of lower limbs","authors":"Z. Krasiński, Z. Gaciong, F. Szymanski, R. Kowalewski, T. Urbanek","doi":"10.5603/AA.2019.0007","DOIUrl":"https://doi.org/10.5603/AA.2019.0007","url":null,"abstract":"Peripheral artery disease (PAD) is a common disease, though not very well known and often diagnosed on a very late stage, causing not only typical complications such as intermittent claudication, critical limb ischemia or amputations, but also to cardiovascular mortality. The risk of cardiovascular death can be even 11 times higher in patients with symptomatic PAD than in healthy patients. The risk of heart attack, stroke or cardiovascular death is even higher, reaching almost 4% within one year, nearly equal to the risk for patients with coronary artery disease (CAD). In those patients, the 5-year mortality risk is estimated at 10–15%, with cardiovascular disorders being the most likely cause of death. In patients with critical limb ischemia, the risk of cardiovascular death within one year can be as high as 25% and the risk of amputation — 30%. It is estimated that the global population of patients with PAD is over 120 million. The incidence of the diseases is 3–10%, but in patients aged 70 and more, the incidence increases to 14–29%. In Poland, around 4,000 people are hospitalized every year for PAD of lower limbs. The number of PAD-related amputations is over 9,000 per year. Although the methods of PAD diagnosis (e.g. ABI) are often easy and non-invasive, they are scarcely used in clinical practice. Also, optimal conservative management in the form of quitting smoking, modifying the cardiovascular risk factors and supervised exercise is often overlooked. PAD is a major issue not only for vascular surgery, but also for many other medical specializations, including angiology, general medicine, cardiology, or diabetology. As a result of long waiting times for the next visit and lack of access to patient programmes and reimbursed drugs, patients with PAD often report to the doctor when their condition is very serious. Despite the 2017 ESC guidelines on the diagnosis and treatment of peripheral artery disease, prepared together with ESVS, not all healthcare professionals have access to the latest knowledge on PAD diagnosis and treatment. Unfortunately, though published recently, the ESC’s guidelines do not include some of the recent studies, among them the possibly breakthrough COMPASS trial which has the potential to change the paradigm of management of patients with PAD. We must bear in mind that the population with PAD is a difficult patient group who need new treatment methods and optimization of the existing ones in order to visibly improve diagnosis, treatment and prognosis.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47657313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.
{"title":"The place of heparins in the treatment of venous thromboembolism","authors":"A. Wojtak, T. Zubilewicz","doi":"10.5603/AA.2019.0006","DOIUrl":"https://doi.org/10.5603/AA.2019.0006","url":null,"abstract":"Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44682285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Feldo, M. Wójciak-Kosior, I. Sowa, J. Kocki, J. Bogucki, T. Zubilewicz, Wacław Karakuła, A. Bogucka-Kocka
Introduction: Primary CVD as a result of increased venous hypertension caused mostly by reflux from valvular incompetence as an indication for venoactive drug treatment. The objective of the study was the association between three months of treatment with diosmin and changes to the angiogenic factors involved in the pathophysiology and clinical symptoms of CVD. Material and methods: 41 patients were included in the study. Plasma levels of tumour necrosis factor a (TNF-a), vascular endothelial growth factor (VEGF-A and VEGF-C), matrix metalloproteinase 9 (MMP-9), Cathepsine-L and endostatin were measured using an ELISA assay at baseline and after three months of diosmin administration. Clinical evaluation was performed using duplex Doppler, the VAS scale, leg circumference measurement and BMI score. Results: Three-month treatment with diosmin was associated with a statistically significant decrease in TNF-a, VEGF-A, VEGF-C, MMP-9, Cathepsin-L and endostatin plasma levels with p < 0.01 and p < 0.05 respectively. The average ankle circumference decreased significantly from 30.45 (± 2.05) to 29.0 (± 1.43) (p < 0.05). Conclusion: Diosmin influence on the inflammatory and proteolytic mechanisms involved in the pathology of CVD, could modify endostatin release and angiogenic processes.
{"title":"Monitoring of endostatin, TNF-a VEGFs, MMP-9, and cathepsin-L during three months of diosmin treatment in patients with chronic venous disease (CVD)","authors":"M. Feldo, M. Wójciak-Kosior, I. Sowa, J. Kocki, J. Bogucki, T. Zubilewicz, Wacław Karakuła, A. Bogucka-Kocka","doi":"10.5603/AA.2019.0002","DOIUrl":"https://doi.org/10.5603/AA.2019.0002","url":null,"abstract":"Introduction: Primary CVD as a result of increased venous hypertension caused mostly by reflux from valvular incompetence as an indication for venoactive drug treatment. The objective of the study was the association between three months of treatment with diosmin and changes to the angiogenic factors involved in the pathophysiology and clinical symptoms of CVD. Material and methods: 41 patients were included in the study. Plasma levels of tumour necrosis factor a (TNF-a), vascular endothelial growth factor (VEGF-A and VEGF-C), matrix metalloproteinase 9 (MMP-9), Cathepsine-L and endostatin were measured using an ELISA assay at baseline and after three months of diosmin administration. Clinical evaluation was performed using duplex Doppler, the VAS scale, leg circumference measurement and BMI score. Results: Three-month treatment with diosmin was associated with a statistically significant decrease in TNF-a, VEGF-A, VEGF-C, MMP-9, Cathepsin-L and endostatin plasma levels with p < 0.01 and p < 0.05 respectively. The average ankle circumference decreased significantly from 30.45 (± 2.05) to 29.0 (± 1.43) (p < 0.05). Conclusion: Diosmin influence on the inflammatory and proteolytic mechanisms involved in the pathology of CVD, could modify endostatin release and angiogenic processes.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47246050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdominal aortic aneurysm (AAA) is a disease affecting the main artery transporting oxidized blood to the abdominal and pelvic organs. Abdominal aortic aneurysms occur 4-8 times more often in men than in women, usually develop after the age of 55. Among men over 65, 4–7.6%, this diagnosis can be expected. More aneurysms occur in Caucasian people. Among the most frequently mentioned in the literature, AAA risk factors are older age, male gender, positive family history, smoking, chronic obstructive pulmonary disease, hypertension, hypercholesterolemia, peripheral arterial occlusive disease, ischemic heart disease. Biochemical tests to determine the level of AAA-specific markers appear with potential. There are reports in the literature on the possible use of concentrations of selected molecules in the diagnosis of AAA. According to cadaveric research, there are noticed dimensions of the abdominal aorta at its different levels. The relation between aortic size and shape can be the factor contributing to the development of AAA. Previous studies have shown that the development of AAA is a crucial fundamental inflammatory response in conjunction with proteolysis tissue, which causes the destruction and reconstruction of the blood vessel wall. Numerous factors contribute to the pathogenesis of AAA: proteins, transcription factors, enzymes and microRNAs. The increase in the concentration of most factors is associated with inflammation. The biomarkers presented in the paper are not limited to AAA, and thus can be used only for visual assessment of the degree of abdominal aortic aneurysm development.
{"title":"The review of selected biomarkers of abdominal aortic aneurysm","authors":"S. Surma, Marta Lesiak, Beata Dorzak, G. Bajor","doi":"10.5603/AA.2019.0004","DOIUrl":"https://doi.org/10.5603/AA.2019.0004","url":null,"abstract":"Abdominal aortic aneurysm (AAA) is a disease affecting the main artery transporting oxidized blood to the abdominal and pelvic organs. Abdominal aortic aneurysms occur 4-8 times more often in men than in women, usually develop after the age of 55. Among men over 65, 4–7.6%, this diagnosis can be expected. More aneurysms occur in Caucasian people. Among the most frequently mentioned in the literature, AAA risk factors are older age, male gender, positive family history, smoking, chronic obstructive pulmonary disease, hypertension, hypercholesterolemia, peripheral arterial occlusive disease, ischemic heart disease. Biochemical tests to determine the level of AAA-specific markers appear with potential. There are reports in the literature on the possible use of concentrations of selected molecules in the diagnosis of AAA. According to cadaveric research, there are noticed dimensions of the abdominal aorta at its different levels. The relation between aortic size and shape can be the factor contributing to the development of AAA. Previous studies have shown that the development of AAA is a crucial fundamental inflammatory response in conjunction with proteolysis tissue, which causes the destruction and reconstruction of the blood vessel wall. Numerous factors contribute to the pathogenesis of AAA: proteins, transcription factors, enzymes and microRNAs. The increase in the concentration of most factors is associated with inflammation. The biomarkers presented in the paper are not limited to AAA, and thus can be used only for visual assessment of the degree of abdominal aortic aneurysm development.","PeriodicalId":41754,"journal":{"name":"Acta Angiologica","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41829241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：